Patent details

301098 Product Name: crizanlizumab

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301098
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2662091
Status:
Application Pending
Application number:
301098
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)

Marketing Authorization

Marketing Authorization Number:
EU/1/20/1476
Marketing Authorization Type:
EEA
Marketing Authorization Date:
29/10/2020
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
01/04/2021
First Marketing Authorization date:
29/10/2020
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
01/04/2021
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
01/04/2021
 
 

 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056, BASEL, Switzerland (CH)

From:
01/04/2021
 
 

 

Name:
Oklahoma Medical Research Foundation
Address:
825 N.E. 13th Street, 73104, Oklahoma City, Oklahoma, United States of America (US)

Agent

1

Name:
dr. R.C. van Duijvenbode c.s.
From:
07/11/2025
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

2

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
01/04/2021
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
07/11/2025

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
14/21
Publication date:
07/04/2021
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
12/02/2026 Incoming Correspondence Electronic Request extension time-limit modifications 1 PDF /4/7/6/3/6/0800663674/docs/301098_6_incomingcorrespondenceelectronic20260212102816408.pdf
12/02/2026 Outgoing Correspondence Letter to applicant 1 PDF /4/7/6/3/6/0800663674/docs/301098_7_301098695476l173.pdf
12/02/2026 Incoming Correspondence Electronic Accompanying letter incoming document 6 PDF /4/7/6/3/6/0800663674/docs/301098_8_incomingcorrespondenceelectronic20260213014547037.pdf
12/02/2026 SPC Documents Annex SPC 3 PDF /4/7/6/3/6/0800663674/docs/301098_9_supplprotectioncertificate20260213014746018.pdf
12/02/2026 SPC Documents Annex SPC 8 PDF /4/7/6/3/6/0800663674/docs/301098_10_supplprotectioncertificate20260213014700259.pdf
12/02/2026 SPC Documents Annex SPC 3 PDF /4/7/6/3/6/0800663674/docs/301098_11_supplprotectioncertificate20260213014621425.pdf
20/11/2025 Outgoing Correspondence Letter to applicant 2 PDF /4/7/6/3/6/0800663674/docs/301098_5_301098683440l173.pdf
06/04/2021 Outgoing Correspondence Confirmation receipt request 1 PDF /4/7/6/3/6/0800663674/docs/301098_1_403790l174.pdf
01/04/2021 SPC Documents Summary of the characteristics of the product 14 PDF /4/7/6/3/6/0800663674/docs/301098_0_supplprotectioncertificate20210401025353088.pdf
01/04/2021 SPC Documents Annex SPC 2 PDF /4/7/6/3/6/0800663674/docs/301098_2_supplprotectioncertificate20210401025245819.pdf
01/04/2021 SPC Documents Marketing Authorization SPC 3 PDF /4/7/6/3/6/0800663674/docs/301098_3_supplprotectioncertificate20210401025154476.pdf
01/04/2021 Application Form First filed application form 2 PDF /4/7/6/3/6/0800663674/docs/301098_4_applicationform20210401024704098.pdf